Literature DB >> 29786758

Long-term complete remission following tandem autologous stem cell transplantation and consolidative radiotherapy for refractory mediastinal gray-zone lymphoma.

Koji Takaishi1, Tomoya Muto1, Naoya Mimura1,2, Jun Takiguchi1, Yuhei Nagao1, Nagisa Oshima-Hasegawa1, Shokichi Tsukamoto1, Yusuke Takeda1, Shio Mitsukawa1,2, Masahiro Takeuchi1, Chikako Ohwada1, Satoshi Ota3, Tohru Iseki1,2, Chiaki Nakaseko1,4, Emiko Sakaida5.   

Abstract

Mediastinal gray zone lymphoma (MGZL) is a provisional entity with intermediate features between classical Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma. Outcomes for patients with MGZL are reportedly poorer than those for patients with cHL or primary mediastinal large B-cell lymphoma. Additionally, no standard management guidelines for patients with MGZL are available, primarily due to its recent identification, rarity, and challenges in diagnosis. Although recent several studies have suggested dose-adjusted EPOCH-R (etoposide, doxorubicin, vincristine, cyclophosphamide, prednisolone, and rituximab) may improve outcomes in patients with MGZL, numerous patients still suffer from relapsed/refractory MGZL, and the optimal management for such patients remains uncertain. Here, we report the first case of successful treatment of refractory MGZL by tandem high-dose chemotherapy supported by autologous stem cell transplantations (auto-SCTs) and consolidative radiotherapy (RT). To date, the patient remains in CR 33 months after the completion of RT, with no significant complications. This case suggests that tandem auto-SCTs may be a promising therapeutic option for relapsed/refractory MGZL.

Entities:  

Keywords:  Gray-zone lymphoma; Radiotherapy; Tandem autologous stem cell transplantations

Mesh:

Substances:

Year:  2018        PMID: 29786758     DOI: 10.1007/s12185-018-2471-x

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  14 in total

Review 1.  Tandem transplantation in lymphoma.

Authors:  K P Papadopoulos; W Noguera-Irizarry; C S Hesdorffer
Journal:  Bone Marrow Transplant       Date:  2001-09       Impact factor: 5.483

2.  Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.

Authors:  Andrew M Evens; Jennifer A Kanakry; Laurie H Sehn; Athena Kritharis; Tatyana Feldman; Aimee Kroll; Randy D Gascoyne; Jeremy S Abramson; Adam M Petrich; Francisco J Hernandez-Ilizaliturri; Zeina Al-Mansour; Camille Adeimy; Jessica Hemminger; Nancy L Bartlett; Anthony Mato; Paolo F Caimi; Ranjana H Advani; Andreas K Klein; Chadi Nabhan; Sonali M Smith; Jesus C Fabregas; Izidore S Lossos; Oliver W Press; Timothy S Fenske; Jonathan W Friedberg; Julie M Vose; Kristie A Blum
Journal:  Am J Hematol       Date:  2015-09       Impact factor: 10.047

3.  A prospective study of mediastinal gray-zone lymphoma.

Authors:  Wyndham H Wilson; Stefania Pittaluga; Alina Nicolae; Kevin Camphausen; Margaret Shovlin; Seth M Steinberg; Mark Roschewski; Louis M Staudt; Elaine S Jaffe; Kieron Dunleavy
Journal:  Blood       Date:  2014-07-14       Impact factor: 22.113

4.  Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma.

Authors:  Yi-Bin Chen; Shuli Li; David C Fisher; Jessica Driscoll; Candice Del Rio; Jeremy Abramson; Philippe Armand; Jeffrey Barnes; Jennifer Brown; Corey Cutler; Areej El-Jawahri; Vincent T Ho; Ephraim Hochberg; Steven McAfee; Ronald Takvorian; Thomas R Spitzer; Joseph H Antin; Robert Soiffer; Eric Jacobsen
Journal:  Biol Blood Marrow Transplant       Date:  2015-05-22       Impact factor: 5.742

Review 5.  How I manage patients with grey zone lymphoma.

Authors:  Athena Kritharis; Monika Pilichowska; Andrew M Evens
Journal:  Br J Haematol       Date:  2016-06-15       Impact factor: 6.998

6.  Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Craig H Moskowitz; Auayporn Nademanee; Tamas Masszi; Edward Agura; Jerzy Holowiecki; Muneer H Abidi; Andy I Chen; Patrick Stiff; Alessandro M Gianni; Angelo Carella; Dzhelil Osmanov; Veronika Bachanova; John Sweetenham; Anna Sureda; Dirk Huebner; Eric L Sievers; Andy Chi; Emily K Larsen; Naomi N Hunder; Jan Walewski
Journal:  Lancet       Date:  2015-03-19       Impact factor: 79.321

Review 7.  The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.

Authors:  Elias Campo; Steven H Swerdlow; Nancy L Harris; Stefano Pileri; Harald Stein; Elaine S Jaffe
Journal:  Blood       Date:  2011-02-07       Impact factor: 22.113

8.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Authors:  Stephen M Ansell; Alexander M Lesokhin; Ivan Borrello; Ahmad Halwani; Emma C Scott; Martin Gutierrez; Stephen J Schuster; Michael M Millenson; Deepika Cattry; Gordon J Freeman; Scott J Rodig; Bjoern Chapuy; Azra H Ligon; Lili Zhu; Joseph F Grosso; Su Young Kim; John M Timmerman; Margaret A Shipp; Philippe Armand
Journal:  N Engl J Med       Date:  2014-12-06       Impact factor: 91.245

9.  Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group.

Authors:  Franck Morschhauser; Pauline Brice; Christophe Fermé; Marine Diviné; Gilles Salles; Reda Bouabdallah; Catherine Sebban; Laurent Voillat; Olivier Casasnovas; Aspasia Stamatoullas; Krimo Bouabdallah; Marc André; Jean-Philippe Jais; Dominique Cazals-Hatem; Christian Gisselbrecht
Journal:  J Clin Oncol       Date:  2008-11-17       Impact factor: 44.544

10.  PD-1 Blockade in Mediastinal Gray-Zone Lymphoma.

Authors:  Christopher Melani; Ajay Major; Jeffrey Schowinsky; Mark Roschewski; Stefania Pittaluga; Elaine S Jaffe; Svetlana D Pack; Zied Abdullaev; Mark A Ahlman; Jennifer J Kwak; Rustain Morgan; Rachel Rabinovitch; Zenggang Pan; Bradley M Haverkos; Jonathan A Gutman; Daniel A Pollyea; Clayton A Smith; Wyndham H Wilson; Manali Kamdar
Journal:  N Engl J Med       Date:  2017-07-06       Impact factor: 91.245

View more
  2 in total

1.  Gray zone lymphoma effectively treated with cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab chemotherapy: A case report.

Authors:  Nobumasa Hojo; Makoto Nagasaki; Yasuha Mihara
Journal:  World J Clin Cases       Date:  2022-06-16       Impact factor: 1.534

2.  Transition Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma- Our Histopathological and Clinical Experience With Patients With Intermediate Lymphoma.

Authors:  Zsófia Simon; Bálint Virga; László Pinczés; Gábor Méhes; Zsófia Miltényi; Sándor Barna; Roxana Szabó; Árpád Illés
Journal:  Pathol Oncol Res       Date:  2021-03-30       Impact factor: 3.201

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.